MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D
Executive Summary
The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.
You may also be interested in...
As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.
MorphoSys Hits Refresh Button On Pipeline With Constellation Buy
The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.
BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut
The company plans to start in Germany with an outcomes-based payment model. But while a US FDA nod seems likely, analysts have been more cautious about calling US approval a done deal.